Dapagliflozin in Heart Failure with Reduced Ejection Fraction: A Real-World Study
Aims: We aimed to observe the improvements in cardiac function indexes and the occurrence of adverse events in patients with heart failure with reduced ejection fraction (HFrEF) after dapagliflozin administration in a real-world setting. Methods: We retrospectively included 201 patients with HFrEF...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Compuscript Ltd
2022-08-01
|
| Series: | Cardiovascular Innovations and Applications |
| Online Access: | https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2022.0005 |
| _version_ | 1797663719789953024 |
|---|---|
| author | Zhengyang Hao Yanzhou Zhang |
| author_facet | Zhengyang Hao Yanzhou Zhang |
| author_sort | Zhengyang Hao |
| collection | DOAJ |
| description | Aims: We aimed to observe the improvements in cardiac function indexes and the occurrence of adverse events in patients with heart failure with reduced ejection fraction (HFrEF) after dapagliflozin administration in a real-world setting. Methods: We retrospectively included 201 patients with HFrEF who were treated at a tertiary hospital in Zhengzhou and started to take dapagliflozin (10 mg/d) from March 2020 to June 2021. Their New York Heart Association (NYHA) functional class, cardiac ultrasound indexes, laboratory indexes, and vital signs between baseline and the last follow-up visit were compared, and their adverse events during the follow-up period were recorded. Results: The follow-up period was 173 (67–210) days. The cardiac function indexes of patients at follow-up, compared with baseline, indicated significant improvement (proportion of NYHA functional class I and II: 40.8% vs. 56.2%; left ventricular ejection fraction: 28.4 ± 5.3% vs. 34.7 ± 5.9%; left ventricular end-diastolic diameter: 70.1 ± 6.4 mm vs. 64.7 ± 5.6 mm; N-terminal pro-B-type natriuretic peptide: 5421.9 ± 2864.4 pg/mL vs. 2842.8 ± 1703.4 pg/mL at baseline vs. at follow-up; all P < 0.05). The rates of hypotension, deterioration of renal function, and genital infection during the follow-up period were 6.5%, 4.0%, and 3.5%, respectively. Conclusions: We believe that dapagliflozin is safe and effective in patients with HFrEF in the real world. |
| first_indexed | 2024-03-11T19:19:50Z |
| format | Article |
| id | doaj.art-19586b29b8d84134bf58599a40761b59 |
| institution | Directory Open Access Journal |
| issn | 2009-8618 2009-8782 |
| language | English |
| last_indexed | 2024-03-11T19:19:50Z |
| publishDate | 2022-08-01 |
| publisher | Compuscript Ltd |
| record_format | Article |
| series | Cardiovascular Innovations and Applications |
| spelling | doaj.art-19586b29b8d84134bf58599a40761b592023-10-07T16:00:15ZengCompuscript LtdCardiovascular Innovations and Applications2009-86182009-87822022-08-016421922310.15212/CVIA.2022.0005Dapagliflozin in Heart Failure with Reduced Ejection Fraction: A Real-World StudyZhengyang HaoYanzhou ZhangAims: We aimed to observe the improvements in cardiac function indexes and the occurrence of adverse events in patients with heart failure with reduced ejection fraction (HFrEF) after dapagliflozin administration in a real-world setting. Methods: We retrospectively included 201 patients with HFrEF who were treated at a tertiary hospital in Zhengzhou and started to take dapagliflozin (10 mg/d) from March 2020 to June 2021. Their New York Heart Association (NYHA) functional class, cardiac ultrasound indexes, laboratory indexes, and vital signs between baseline and the last follow-up visit were compared, and their adverse events during the follow-up period were recorded. Results: The follow-up period was 173 (67–210) days. The cardiac function indexes of patients at follow-up, compared with baseline, indicated significant improvement (proportion of NYHA functional class I and II: 40.8% vs. 56.2%; left ventricular ejection fraction: 28.4 ± 5.3% vs. 34.7 ± 5.9%; left ventricular end-diastolic diameter: 70.1 ± 6.4 mm vs. 64.7 ± 5.6 mm; N-terminal pro-B-type natriuretic peptide: 5421.9 ± 2864.4 pg/mL vs. 2842.8 ± 1703.4 pg/mL at baseline vs. at follow-up; all P < 0.05). The rates of hypotension, deterioration of renal function, and genital infection during the follow-up period were 6.5%, 4.0%, and 3.5%, respectively. Conclusions: We believe that dapagliflozin is safe and effective in patients with HFrEF in the real world.https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2022.0005 |
| spellingShingle | Zhengyang Hao Yanzhou Zhang Dapagliflozin in Heart Failure with Reduced Ejection Fraction: A Real-World Study Cardiovascular Innovations and Applications |
| title | Dapagliflozin in Heart Failure with Reduced Ejection Fraction: A Real-World Study |
| title_full | Dapagliflozin in Heart Failure with Reduced Ejection Fraction: A Real-World Study |
| title_fullStr | Dapagliflozin in Heart Failure with Reduced Ejection Fraction: A Real-World Study |
| title_full_unstemmed | Dapagliflozin in Heart Failure with Reduced Ejection Fraction: A Real-World Study |
| title_short | Dapagliflozin in Heart Failure with Reduced Ejection Fraction: A Real-World Study |
| title_sort | dapagliflozin in heart failure with reduced ejection fraction a real world study |
| url | https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2022.0005 |
| work_keys_str_mv | AT zhengyanghao dapagliflozininheartfailurewithreducedejectionfractionarealworldstudy AT yanzhouzhang dapagliflozininheartfailurewithreducedejectionfractionarealworldstudy |